Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mira PharmaceuticalsMIRA +4.01%13 Cash Ratio is 197.88 as of Jun. 2026, which is 3209% above its 10-year median of 5.98. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 970 Drug Manufacturers companies, Mira Pharmaceuticals ranks better than 99.69% on this metric.
Mira Pharmaceuticals has a Cash Ratio of 197.88. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Mira Pharmaceuticals's Cash Ratio or its related term are showing as below:
MIRA'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 5.98 Max: 197.88
Current: 197.88
During the past 5 years, Mira Pharmaceuticals's highest Cash Ratio was 197.88. The lowest was 0.01. And the median was 5.98.
MIRA's Cash Ratio is ranked better than 99.69% of 970
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs MIRA: 197.88
Mira Pharmaceuticals (NAS:MIRA) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Mira Pharmaceuticals Cash Ratio Related Terms
Mira Pharmaceuticals Cash Ratio Historical Data
* Premium members only.
The historical data trend for Mira Pharmaceuticals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals (MIRA) has a Cash Ratio of 197.88 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Mira Pharmaceuticals and its competitors. This is 3209% above median its historical median of 5.98. Over the past decade, Mira Pharmaceuticals' Cash Ratio has ranged from 0.01 to 197.88. According to the industry distribution chart, Mira Pharmaceuticals ranks #3 out of 970 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Mira Pharmaceuticals' Cash Ratio too high?
Mira Pharmaceuticals' current Cash Ratio of 197.88 is 3209% above median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 197.88. The Drug Manufacturers industry median Cash Ratio is 0.59. Mira Pharmaceuticals' value of 197.88 is 33439% above this industry median. Based on the distribution chart, Mira Pharmaceuticals ranks #3 out of 970 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' Cash Ratio compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #3 out of 970 companies for Cash Ratio. This places Mira Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.59. Mira Pharmaceuticals' value of 197.88 is 33439% above this benchmark. Historically, Mira Pharmaceuticals' own Cash Ratio has ranged from 0.01 to 197.88 over the past decade. While the company's 10-year median is 5.98 vs. the industry median of 0.59, Mira Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.59, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mira Pharmaceuticals's current Cash Ratio of 197.88 is 33439% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current Cash Ratio is 197.88, which is 3209% above median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current Cash Ratio of 197.88. The current Cash Ratio is 197.88, which is 3209% above median its 10-year median of 5.98 and 33439% above the Drug Manufacturers industry median of 0.59. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current Cash Ratio is 197.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
